PTAB
Advanced fields
248 decisions · 510msnewest first
  • Snap Inc. v. You Map Inc.All claims unpatentable
    PTAB · May 4, 2026 · IPR2022-00568 · APJ Jason M Repko · IPR · Remand

    Claims 1–20 remain unpatentable; the contingent motion to amend is denied because the proposed substitute claims would have been obvious over Feldman and Jackson in view of ordinary skill.

    RulingsRemand decision
    • RemandDecided for patent owner

      “challenge fails even if Petitioner’s summary of the references were correct because Petitioner did not present a sufficient reason to modify Feldman to include a current zoom level in its search request. FWD 56. The Federal Circuit vacated this finding specifically and contemplated that there would be a “consideration of obviousness” on remand. CAFC Dec. 10–11. That consideration requires more than determining whether any one reference teaches a current zoom level and a search, generally. See FWD 56 (quoting MTA Reply 10). Here, Petitioner’s challenge is based on modifying the Feldman-Jackson combination. So the Board must determine on remand whether the Feldman-Jackson combination in view of knowledge of a POSA meets the claim limitations at issue. We also disagree to the extent that Petitioner argues that the Board is precluded from considering additional arguments on the relevant issues on remand. The Board’s preliminary guidance on the Motion to Amend stated that Petitioner’s obviousness rationale was based on convenience and this reason was not sufficiently supported: reference lacks a sufficient explanation of why one of ordinary skill in the art would have added the zoom levels in the prior art to Feldman. See id. At most, Petitioner argues that it would be convenient to “specify the area the user desires to search for content” in this way. Id. at 14. But, on this record, Petitioner has not sufficiently explained why it would be convenient to do so in Feldman. See id. Nor has Petitioner sufficiently explained how or why the prior-art features confer this convenience. See id. MTA PG, 13. Because the Board’s conclusion turned on the lack of sufficient explanation, the briefing that followed was limited to Petitioner’s obviousness rationale. See, e.g., MTA Reply 9–12, MTA Sur-reply 1–12. Under these specific circumstances, we determine that it would be procedurally fair to fully consider the arguments on remand about whether the cited prior art teaches or suggests the limitations recited in the substitute claims. And, as discussed above, the Federal Circuit has directed the Board to consider obviousness. CAFC Dec. 10–11.” slip op. at 11

    • Skill levelSkill level petitioner adoptedDecided for petitioner

      “Patent Owner does not contest Petitioner’s proposed level of ordinary skill in the art. See PO Resp.; Sur-reply. Patent Owner’s expert, Dr. Shamos, and provides substantially the same expression of the level of ordinary skill in the art. Ex, 2003 ¶¶ 30–31; see FWD 6–7. In this Decision, we apply Petitioner’s proposed definition.” slip op. at 6

    • PTAB / AIA Trials › Motions to amend / substitute claimsMotion to amend, deniedDenied

      “In sum, Petitioner has shown that replacing Feldman’s radius with Badger’s zoom level meets all the limitations of the claim considered in the context of the Feldman-Jackson combination. Also, the evidence shows a motivation to modify the radius in Feldman’s search request to instead be based on the zoom-level parameter disclosed in Badger. See Intel Corp. v. PACT XPP Schweiz AG, 61 F.4th 1373, 1380–81 (Fed. Cir. 2023) (“There is a motivation to combine when a known technique ‘has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way,’ . . . using the ‘prior art elements according to their established functions.’”) (citing KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 417 (2007)). substitute claim 21 is unpatentable over Feldman, Jackson, and knowledge of one of ordinary skill in the art. See Koninklijke Philips N.V. v. Google LLC, 948 F.3d 1330, 1337 (Fed. Cir. 2020) (“[U]nder 35 U.S.C. § 103, the obviousness inquiry turns not only on the prior art, but whether ‘the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious . . . to a person having ordinary skill in the art to which the claimed invention pertains.’”).” slip op. at 19

    • Strike new argumentNew argument consideredDecided for patent owner

      “precluded from considering additional arguments on the relevant issues on remand. The Board’s preliminary guidance on the Motion to Amend stated that Petitioner’s obviousness rationale was based on convenience and this reason was not sufficiently supported: reference lacks a sufficient explanation of why one of ordinary skill in the art would have added the zoom levels in the prior art to Feldman. See id. At most, Petitioner argues that it would be convenient to “specify the area the user desires to search for content” in this way. Id. at 14. But, on this record, Petitioner has not sufficiently explained why it would be convenient to do so in Feldman. See id. Nor has Petitioner sufficiently explained how or why the prior-art features confer this convenience. See id. MTA PG, 13. Because the Board’s conclusion turned on the lack of sufficient explanation, the briefing that followed was limited to Petitioner’s obviousness rationale. See, e.g., MTA Reply 9–12, MTA Sur-reply 1–12. Under these specific circumstances, we determine that it would be procedurally fair to fully consider the arguments on remand about whether the cited prior art teaches or suggests the limitations recited in the substitute claims. And, as discussed above, the Federal Circuit has directed the Board to consider obviousness. CAFC Dec. 10–11.” slip op. at 11

    Patent outcomesUS 10,616,727 unpatentable
    § 103 obviousnesscites KSR
    Patents in suitUS 10,616,727
  • PTAB · Jan 22, 2026 · IPR2024-01094 · APJ Grace Karaffa Obermann · IPR · Final written decision

    Claims 1, 2, 6, and 8–14 are unpatentable as obvious over Ma; claims 3 and 4 were not shown unpatentable over Werner.

    RulingsFinal written decision
    • Skill levelSkill level petitioner adoptedDecided for petitioner

      “Petitioner contends: A person of ordinary skill in the art (“POSA”) at the time of the alleged invention of the ’223 patent would have had a university degree in chemistry and additional expertise or a second university degree in the field of electrical engineering, particularly optoelectronics, or alternatively a university degree in electrical engineering and additional expertise or a second university degree in the field of chemistry. The person of ordinary skill in the art has spent several years studying the structure and function of organic optoelectronic components, in particular OLEDs, and has detailed knowledge of the chemical structure of light-emitting organic layers and the transport of charge carriers to these layers. In this respect, the person of ordinary skill in the art works at the interface between electrical engineering/physics (charge carrier transport and light emission processes in optoelectronic components) and chemistry, in particular organic chemistry (materials and layer stack combinations suitable). Pet. 14 (citing Ex. 1003 ¶¶ 46–47). Patent Owner does not dispute Petitioner’s contention. See generally Resp. Neither party indicates that the result would change depending on the definition selected. We adopt Petitioner’s uncontested proposed definition, because it is consistent with the disclosures of the asserted prior art references. See Ex. 1005, (code 57); Ex. 1007, 8107 (abstracts of the references asserted in the patentability challenges).” slip op. at 8

    • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther

      “history pertaining to the patent.” 37 C.F.R. § 42.100(b). Under that standard, claim terms generally are given their plain and ordinary meaning as would have been understood by the ordinarily skilled artisan at the time of the invention and within the context of the entire patent disclosure. See Phillips v. AWH Corp., 415 F.3d 1303, 1313 (Fed. Cir. 2005) (en banc). We construe claim terms only as relevant to the parties’ contentions and only to the extent necessary to resolve the issues in dispute. See Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999); Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., 868 F.3d 1013, 1017 (Fed. Cir. 2017). Neither party indicates that an express construction for any claim term is necessary to resolve the disputes at hand. Pet. 15; see generally Resp. On this record, we determine that no claim term requires express construction for purposes of this Decision. In our analysis of the challenges, however, we discuss the meaning of the terms “metal complex” and “central metal atom,” which appear in claim 1 (Ex. 1001, 19:19–20) to the extent necessary to resolve Patent Owner’s contention that Petitioner fails to establish that Ma invalidates claim 1. See Resp. 53, 56–58.” slip op. at 9

    • Novelty / Anticipation (§102) › Prior-art status of a reference › Printed publication / public accessibilityPrinted publication establishedDecided for petitioner

      “Whether Ma qualifies as a “printed publication” involves an inquiry into the facts and circumstances surrounding the reference’s disclosure to members of the public. In re Klopfenstein, 380 F.3d 1345, 1350 (Fed. Cir. 2004). A reference is considered “publicly accessible” upon a satisfactory showing that the document has been “disseminated or otherwise made available to the extent that persons interested and ordinarily skilled in the subject matter or art exercising reasonable diligence[] can locate it.” Kyocera Wireless Corp. v. ITC, 545 F.3d 1340, 1350 (Fed. Cir. 2008); see Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, Paper 29, 10– 11 (PTAB Dec. 20, 2019) (precedential).” slip op. at 10

    • Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundUnpatentable

      “Based on the information presented, we find Petitioner has the better position. Patent Owner admits that joint vaporization means “two materials vaporize together.” Reply 21 (quoting Resp. 54). As Petitioner argues, “This is what Ma discloses.” Id. We agree with Petitioner that Ma describes a “two-component” electron transport layer having a “thickness with one value.” Id.; see Ex. 1007, 811 (reporting a “co-deposited” application of “BPhen:LiQ” that is “50 nm thick”). Ma’s disclosure, thereby, strongly “indicates that the two components were vaporized together––as opposed to creating a ‘macroscopically homogenous form’” prepared by sequentially vaporizing the individual components as Patent Owner “hypothesizes.” Reply 21 (citing Ex. 1020 ¶¶ 42–44; Ex. 2041 ¶¶ 155–157); see Resp. 54– 55; see also Ex. 1007, 811 (Ma’s description of its device fabrication, appearing in the third paragraph of the experiments section). Petitioner further advances evidence that “[p]reparing a layer that is ‘macroscopically homogeneous’ but potentially microscopically heterogeneous,” as Patent Owner postulates, “would introduce excessive variability and render the data noncomparable and unreliable, thus undermining the experiment’s purpose.” Reply 21 (citing Ex. 1020 ¶ 44); see Resp. 54–55. Patent Owner presents no counterargument or evidence that is persuasive to undercut Petitioner’s reasoning or evidence on that point. See Sur-reply 19–22. Petitioner also argues that an ordinarily skilled artisan would have recognized “that vaporizing materials together would best achieve Ma’s objective of assessing the current density using different Liq doping percentages.” Reply 22 (citing Ex. 1007, 811; Ex. 1020 ¶ 51). Here again, Petitioner’s evidence on point stands uncontested. See Sur-reply 19–22 (declining to contest that point). On this record, therefore, we agree with Petitioner that, as to the relevant disclosure in Ma, “the most natural interpretation of ‘co-deposition’ for forming a layer, particularly when there is nothing to indicate that the materials” are “vaporized sequentially,” is that the materials are co-deposited by joint vaporization. Reply 22 (citing Ex. 1020 ¶ 46–51). We further agree that, “[u]nder a preponderance standard, Ma’s disclosures are sufficient to render joint vaporization at least obvious.” Id. For the above reasons, we determine that Petitioner demonstrates by a preponderance of the evidence that Ma discloses joint vaporization as required by the challenged claims.” slip op. at 15

    Patent outcomesUS 8,558,223 mixed
    Claim construction§ 102 anticipation§ 103 obviousnesscites Phillips · Graham
    Patents in suitUS 8,558,223
  • PTAB · Dec 19, 2025 · IPR2025-00740 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Patent Owner’s motions to dismiss and entered adverse judgment after Patent Owner disclaimed all challenged claims in the captioned trials.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 10,828,559
  • PTAB · Dec 19, 2025 · IPR2025-00703 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Patent Owner’s motions to dismiss and entered adverse judgment against it on claims 1, 2, 11, and 13 of the challenged patent after their disclaimer.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted

      “above-captioned cases requesting inter partes review of certain claims (“the challenged claims”) of the subject U.S. Patents. See, e.g., IPR2025-00702, Paper 1. Mullen Industries LLC (“Patent Owner”) filed Preliminary Responses to the Petitions. See, e.g., IPR2025-00702, Paper 10. Because we determined that Petitioner had demonstrated a reasonable likelihood that it would prevail with respect to at least one challenged claim in each case, we instituted inter partes review of all challenged claims on all asserted grounds in all of the cases. See, e.g., IPR2025-00702, Paper 11.” slip op. at 2

    None
    Patents in suitUS 11,033,821
  • PTAB · Dec 19, 2025 · IPR2025-00702 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Mullen’s motions to dismiss and entered adverse judgment after Mullen disclaimed all challenged claims in the instituted trials.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Motion to exclude, deniedDenied

      “Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 10,967,270
  • PTAB · Dec 19, 2025 · IPR2025-00737 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Mullen’s motions to dismiss and entered adverse judgment against it on claims 1, 2, 4-7, 13, and 17 after those claims were disclaimed post-institution.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “We determine that Petitioner has the better position. Our rules provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 8,585,476
  • PTAB · Dec 19, 2025 · IPR2025-00738 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Patent Owner’s motions to dismiss and entered adverse judgment after Patent Owner disclaimed all challenged claims, including claims 1, 2, 11, and 13 of the ’582 patent.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 9,744,448
  • PTAB · Dec 19, 2025 · IPR2025-00739 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Mullen’s motions to dismiss and entered adverse judgment against it for challenged claims 1, 8, 13, and 20 of U.S. Patent 10,179,277 after their post-institution disclaimer.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “We determine that Petitioner has the better position. Our rules provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 10,179,277
  • PTAB · Dec 19, 2025 · IPR2025-00741 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Patent Owner’s dismissal motions and entered adverse judgment against Mullen Industries LLC on claims 1, 12, 17, and 20 of U.S. Patent 11,376,493 B2 after disclaimer.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 11,376,493
  • PTAB · Dec 19, 2025 · IPR2025-00742 · APJ Ken B Barrett · IPR · Adverse judgment

    The Board denied Patent Owner’s dismissal motions and entered adverse judgment against it for the disclaimed challenged claims in the listed proceedings.

    RulingsAdverse judgment
    • Adverse judgmentAdverse judgmentGranted

      “We determine that Petitioner has the better position. Our rules provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6

    • PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied

      “In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3

    None
    Patents in suitUS 11,904,243
Page 1 of 25
← Previous12345…Next →

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.